A citation-based method for searching scientific literature

Sohita Dhillon. Drugs 2019
Times Cited: 8







List of co-cited articles
21 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
951
37

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N. Engl. J. Med. 2019
532
37

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Sreeneeranj Kasichayanula, Xiaoni Liu, Frank Lacreta, Steven C Griffen, David W Boulton. Clin Pharmacokinet 2014
97
37

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
58
25

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
133
25

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
80
25


Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
120
25



Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2019
19
25

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
52
25




SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li,[...]. Cardiovasc Diabetol 2019
56
25

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
M Arow, M Waldman, D Yadin, V Nudelman, A Shainberg, N G Abraham, D Freimark, R Kornowski, D Aravot, E Hochhauser,[...]. Cardiovasc Diabetol 2020
6
33

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
362
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
25

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
25

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N. Engl. J. Med. 2016
25

SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
Nabila Ahmed-Sarwar, Angela K Nagel, Samantha Leistman, Kevin Heacock. Ann Pharmacother 2017
6
16

Glycemic Variability: How Do We Measure It and Why Is It Important?
Sunghwan Suh, Jae Hyeon Kim. Diabetes Metab J 2015
103
12

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
10
12

Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes.
Ava S Runge, Lynn Kennedy, Adam S Brown, Abigail E Dove, Brian J Levine, Sophie P Koontz, Varun S Iyengar, Sarah A Odeh, Kelly L Close, Irl B Hirsch,[...].  2018
23
12

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.
Roy W Beck, Richard M Bergenstal, Tonya D Riddlesworth, Craig Kollman, Zhaomian Li, Adam S Brown, Kelly L Close. Diabetes Care 2019
103
12




The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
30
12

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
636
12




Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.
Friedrich Mittermayer, Erica Caveney, Claudia De Oliveira, G Alexander Fleming, Loukas Gourgiotis, Mala Puri, Li-Jung Tai, J Rick Turner. Curr Diabetes Rev 2017
5
20

SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
30
12


International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
62
12

Bioavailability of phloretin and phloridzin in rats.
V Crespy, O Aprikian, C Morand, C Besson, C Manach, C Demigné, C Rémésy. J. Nutr. 2001
69
12

Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis.
S Laberge, O Ghaffar, M Boguniewicz, D M Center, D Y Leung, Q Hamid. J. Allergy Clin. Immunol. 1998
54
12

Effects of phloretin on oxidative and inflammatory reaction in rat model of cecal ligation and puncture induced sepsis.
Mehdi Aliomrani, Mohammad Reza Sepand, Hamid Reza Mirzaei, Ali Reza Kazemi, Saeid Nekonam, Omid Sabzevari. Daru 2016
17
12

TargetATPsite: a template-free method for ATP-binding sites prediction with residue evolution image sparse representation and classifier ensemble.
Dong-Jun Yu, Jun Hu, Yan Huang, Hong-Bin Shen, Yong Qi, Zhen-Min Tang, Jing-Yu Yang. J Comput Chem 2013
36
12

Role of Apple Phytochemicals, Phloretin and Phloridzin, in Modulating Processes Related to Intestinal Inflammation.
Danuta Zielinska, José Moisés Laparra-Llopis, Henryk Zielinski, Dorota Szawara-Nowak, Juan Antonio Giménez-Bastida. Nutrients 2019
7
14

Eczema and cardiovascular risk factors in 2 US adult population studies.
Jonathan I Silverberg, Philip Greenland. J. Allergy Clin. Immunol. 2015
106
12

Animal models of atopic dermatitis.
Haoli Jin, Rui He, Michiko Oyoshi, Raif S Geha. J. Invest. Dermatol. 2009
240
12

Atopic dermatitis.
Stephan Weidinger, Natalija Novak. Lancet 2016
488
12


Immunomodulation of phloretin by impairing dendritic cell activation and function.
Chi-Chen Lin, Ching-Liang Chu, Chin-Sheng Ng, Ching-Yen Lin, Der-Yuan Chen, I-Hong Pan, Kao-Jean Huang. Food Funct 2014
17
12


Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.
Lawrence F Eichenfield, Wynnis L Tom, Timothy G Berger, Alfons Krol, Amy S Paller, Kathryn Schwarzenberger, James N Bergman, Sarah L Chamlin, David E Cohen, Kevin D Cooper,[...]. J. Am. Acad. Dermatol. 2014
346
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.